PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
49 hedge funds and large institutions have $14M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
49
Holders Change
-7
Holders Change %
-12.5%
% of All Funds
0.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
12
Reduced
13
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
SSA
51
Schonfeld Strategic Advisors
New York
| – | -$34K | -25,500 | Closed |
|
|
CSS
52
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$27K | -20,143 | Closed |
|
|
EMG
53
ETF Managers Group
Summit,
New Jersey
| – | -$21K | -14,587 | Closed |
|
|
SWM
54
Spire Wealth Management
Mclean,
Virginia
| – | -$11K | -8,000 | Closed |
|
|
CAGAS
55
Capital Advisory Group Advisory Services
Bloomington,
Minnesota
| – | -$4K | -2,800 | Closed |
|
56
Simplex Trading
Chicago,
Illinois
| – | -$1K | -927 | Closed |
|